[KongchangAI]
Unverified80% confidenceDecision RuleTime unknown

对于需要更强效或起效更快的过敏性鼻炎控制,口碑反馈中部分用户会转向其活性代谢产物地氯雷他定(如恩理思),后者理论上起效略快、个体差异更小

1
Sources
80%
Confidence
Long-term
Relevance
-
First Seen

Sources

Related Entities

Related Claims

Cite This Claim

Stable URI
https://kongchang.com/claim/644138
API
curl https://kongchang.com/api/v1/knowledge/claims/644138
MCP
get_claim(id=644138)